SCHEMBL8279956

SCHEMBL8279956

CCn1c(=O)nc(C=O)[nH]c1=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 3/20 0.36
▸ MEN1 O00255 3/20 0.36
▸ KMT2A Q03164 3/20 0.36
▸ MAPT P10636 3/20 0.36
▸ POLB P06746 1/20 0.36
▸ PDE4A P27815 2/20 0.36
▸ ADORA2A P29274 2/20 0.36
▸ PDE4B Q07343 2/20 0.36
▸ PDE4C Q08493 2/20 0.36
▸ PDE4D Q08499 2/20 0.36
▸ LMNA P02545 2/20 0.34
▸ SMN1; SMN2 Q16637 2/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ CYP2D6 P10635 1/20 0.34
▸ TSHR P16473 1/20 0.34
▸ NFKB1 P19838 1/20 0.34
▸ BLM P54132 1/20 0.34
▸ PMP22 Q01453 1/20 0.34
▸ ADORA3 P0DMS8 1/20 0.34
▸ ADORA2B P29275 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2551065 0.75 ADORA2B (0.55) MEN1KMT2APDE4AADORA2APDE4B
SCHEMBL14306613 0.75 CHRNB2 (0.41) MEN1KMT2AMAPTADORA2ALMNA
SCHEMBL8279930 0.73 CYP1A2 (0.38) CYP1A2MEN1KMT2AMAPTPOLB
SCHEMBL11479633 0.70 MAT2A (0.41) CYP1A2MEN1KMT2AMAPTPOLB
SCHEMBL8279958 0.69 LMNA (0.40) CYP1A2MEN1KMT2AMAPTPOLB
SCHEMBL12043303 0.66 PTGER4 (0.39) MEN1KMT2APDE4AADORA2APDE4B
SCHEMBL163183 0.64 MAPT (0.47) CYP1A2MEN1KMT2AMAPTPOLB
SCHEMBL633733 0.64 CYP1A2 (0.47) CYP1A2MEN1KMT2AMAPTPOLB
SCHEMBL8279966 0.63 ALDH1A1 (0.49) CYP1A2MEN1KMT2AMAPTPOLB
SCHEMBL3519626 0.63 ADORA2B (0.40) CYP1A2MEN1KMT2AMAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8372973-B2 Prokineticin 1 receptor antagonists JANSSEN PHARMACEUTICA N.V. (BE) 2013-02-12 — — US disclosed
US-8362247-B2 Prokineticin 1 receptor antagonists JANSSEN PHARMACEUTICA N.V. (BE) 2013-01-29 — — US disclosed
US-20120245077-A1 PROKINETICIN 1 RECEPTOR MABUS JOHN R (US) 2012-09-27 — — US disclosed
US-8188081-B2 Methods of treating inflammation using prokineticin 1 receptor antagonists JANSSEN PHARMACEUTICA, NV (BE) 2012-05-29 — — US disclosed
US-20120129862-A1 PROKINETICIN 1 RECEPTOR ANTAGONISTS COATS STEVEN J (US) 2012-05-24 — — US disclosed
US-20120028997-A1 PROKINETICIN 1 RECEPTOR ANTAGONISTS COATS STEVEN J (US) 2012-02-02 — — US disclosed
US-20110319400-A1 PROKINETICIN 1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN JANSSEN PHARMACEUTICA, NV (BE) 2011-12-29 — — US disclosed
US-20110319418-A1 PROKINETICIN 1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN JANSSEN PHARMACEUTICA, NV (BE) 2011-12-29 — — US disclosed
US-20110136811-A1 PROKINETICIN 1 RECEPTOR MABUS JOHN R 2011-06-09 — — US disclosed
US-7902358-B2 Gastrointestinal disorders; inflammatory bowel disorders; gastroesophageal reflux, constipation; diarrhea JANSSEN PHARMACEUTICA NV (BE) 2011-03-08 — — US disclosed
US-7825117-B2 Methods of modulating intestine epithelial functions JANSSEN PHARMACEUTICA NV (BE) 2010-11-02 — — US disclosed
US-20080287445-A1 Prokineticin 2 receptor antagonists JANSSEN PHARMACEUTICA N.V. (BE) 2008-11-20 — — US disclosed
US-20080269225-A1 Prokineticin 1 receptor antagonists JANSSEN PHARMACEUTICA N.V. (BE) 2008-10-30 — — US disclosed
US-20080045535-A1 Prokineticin 2 receptor antagonists JANSSEN PHARMACEUTICA N.V. (BE) 2008-02-21 — — US disclosed
US-20070021422-A1 Prokineticin 1 receptor JANSSEN PHARMACEUTICA NV (BE) 2007-01-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045535-A1 Prokineticin 2 receptor antagonists PROKR2, PROKR1, GIPR CYP1A2 2089/4885MEN1 558/4885KMT2A 4161/4885
US-20120028997-A1 PROKINETICIN 1 RECEPTOR ANTAGONISTS PROKR1, PROKR2, GIPR CYP1A2 3611/4885MEN1 295/4885KMT2A 4664/4885
US-20110319400-A1 PROKINETICIN 1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN PROKR1, OPRL1, PROKR2 CYP1A2 3333/4885MEN1 1720/4885KMT2A 4496/4885
US-20110136811-A1 PROKINETICIN 1 RECEPTOR PROKR1, PROKR2, GIPR CYP1A2 3130/4885MEN1 292/4885KMT2A 4529/4885
US-20120129862-A1 PROKINETICIN 1 RECEPTOR ANTAGONISTS PROKR1, PROKR2, GIPR CYP1A2 3611/4885MEN1 295/4885KMT2A 4664/4885
US-20080269225-A1 Prokineticin 1 receptor antagonists PROKR1, PROKR2, GIPR CYP1A2 3611/4885MEN1 295/4885KMT2A 4664/4885
US-20110319418-A1 PROKINETICIN 1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN PROKR1, OPRL1, PROKR2 CYP1A2 3136/4885MEN1 1815/4885KMT2A 4398/4885
US-20070021422-A1 Prokineticin 1 receptor PROKR1, PROKR2, GIPR CYP1A2 3130/4885MEN1 292/4885KMT2A 4529/4885
US-20120245077-A1 PROKINETICIN 1 RECEPTOR PROKR1, PROKR2, GIPR CYP1A2 3130/4885MEN1 292/4885KMT2A 4529/4885
US-20080287445-A1 Prokineticin 2 receptor antagonists PROKR2, PROKR1, GIPR CYP1A2 2416/4885MEN1 1057/4885KMT2A 4082/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback